Company Long-Term Loans and Borrowings: Moderna Corp (MRNA)

Public company logo of Moderna Inc (MRNA)

The long-term loans and borrowings chart for Moderna, Inc. (MRNA) demonstrates the impact of a scalable mRNA platform with high barriers to entry. The current metric value of 1.19 is driven by geopolitical risks hindering the global distribution of drugs. Simultaneously, the financial burden is being adjusted through the implementation of AI robotics, which automates sequence synthesis in cloud complexes to optimize costs.

MRNA Moderna, Inc. Company Long-Term Debts (07/04/2022 - 10/29/2026)

Moderna Corp (MRNA) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price modernatx.com|MRNA - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Moderna|MRNA - Total Company Value
- book capitalization information:
Accounting Value per Share Moderna|MRNA - Book Capitalization|Market Capitalization to Book Value Ratio modernatx.com|MRNA - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Moderna, Inc.|MRNA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Moderna Therapeutics|MRNA - Company Debts|Debt to Book Value Ratio Moderna|MRNA - Company Long-Term Debts|Current Liabilities Moderna|Immediate Liquidity modernatx.com
- earnings and multiples data:
MRNA - Net Profit
Analysis of all company metrics:modernatx.com - MRNA
Brand item of Moderna, Inc.

Moderna, Inc. (MRNA) maintains its leadership in mRNA technologies, yet faces declining revenues from COVID-19 vaccines. This metric measures the aggregate of obligations with maturities exceeding one year, reflecting the business's ability to fund expansion without the risk of default. An analysis of the organization's long-term financial debt structure on GURU.Markets allows for an assessment of borrowing rates used to develop new respiratory products. A stable debt level would confirm the company's resilience during the market cycle transition.

Who Moderna, Inc. competes with

Company Long-Term Debts summittxinc.com SMMT|PCVX - Company Long-Term Debt|Company Long-Term Loans and Borrowings TARS (Tarsus Pharmaceuticals Inc)|CorMedix Corp (CRMD) - Company Long-Term Debt|Company Long-Term Liabilities Seres Therapeutics, Inc|SPRO (Spero Therapeutics) - Company Long-Term Debts|Company Long-Term Debts Scynexis|Company Long-Term Liabilities ANTX (AN2 Therapeutics, Inc.)|PYPD (polypid.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts LSB (YS Biopharma)|Long-Term Debt Volume Iterum Therapeutics PLC (ITRM)|PHGE - Company Long-Term Debt|SNGX (Soligenix, Inc.) - Company Long-Term Indebtedness|SXTP: Company Long-Term Debts|Long-Term Liabilities OGEN (Oragenics Inc.)|ONCO (Onconetix Corp) - Company Long-Term Debts|Long-Term Debt OpGen Corporation OPGN